Neues Anwendungsgebiet: Schlafstörungen bei neurogenetischen Erkrankungen; ≥ 2 bis ≤ 18 Jahre
G-BA action
discontinuation
2024-10-17
Evidence-checked summary
The G-BA issued a discontinuation on 2024-10-17. The official page states that it took effect as follows: 17.10.2024. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Official case record
No inferred stages
Consultation record
No official oral hearing is attached to this case.
IQWiG comparison
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
No IQWiG assessment reference is present on the validated official case page. This is an explicit absence, not a broken graph link.
G-BA decisions
2024-10-17
discontinuation
The G-BA issued a discontinuation on 2024-10-17. The official page states that it took effect as follows: 17.10.2024. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
2 official documents · 3 cited claims
Official sources